3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Lung Neoplasms
2
Breast Neoplasms
2
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Nivolumab
5
aldesleukin
3
Ipilimumab
3
Blood Specimen Collection
3
relatlimab
2
Vemurafenib
2
Immune Checkpoint Inhibitors
2
trametinib
1
technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran
1
technetium Tc 99m nanocolloid
1
sargramostim
1
pembrolizumab
1
pasireotide
1
encorafenib
1
dabrafenib
1
binimetinib
1
Vindesine
1
Standard of Care
1
Specimen Handling
1
Sevoflurane
1
Propofol
1
Pharmaceutical Preparations
1
Patient-Specific Modeling
1
Isoflurane
1
Interleukins
1
Interleukin-2
1
Granulocyte-Macrophage Colony-Stimulating Factor
1
Fibrin Tissue Adhesive
1
Etanercept
1
Desflurane
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 4
×
Melanoma
×
Isoflurane
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled